Human cells transformed by SV40 revisited: the epithelial cells

A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).

BMC cancer·2023

Absolute Percentage of Pattern 4 Disease as a Prognostic Measure for Intermediate-risk Prostate Cancer Treated with Stereotactic Body Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022

Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021

MRI-guided radiotherapy for head and neck cancer: initial clinical experience.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2017

Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.

Prostate cancer and prostatic diseases·2017